Macrogenics (MGNX) Cost of Revenue (2021 - 2026)
Macrogenics (MGNX) posted quarterly Cost of Revenue of $233000.0 for Q4 2024, up 42.94% year-over-year from $163000.0 in Q1 2024, and up 38.69% quarter-over-quarter from $168000.0 in Q3 2024.
Powered by 
Analysis
Macrogenics (MGNX) Cost of Revenue (2021 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Cost of Revenue for 4 consecutive years, with $233000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Cost of Revenue rose 42.94% year-over-year to $233000.0; the TTM figure through Sep 2025 stood at $233000.0 (down 70.01% YoY), while the FY2024 annual figure was $847000.0, up 36.83% from the prior year.
- Cost of Revenue climbed to $233000.0 in Q4 2024 per MGNX's latest filing, from $168000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $3.0 million in Q3 2022 and bottomed at $17000.0 in Q1 2021.
- Historically, Cost of Revenue has averaged $466750.0 across 4 years, with a median of $172000.0 in 2024.
- Annual changes were most pronounced in 2022 — Cost of Revenue soared 718.18% — and 2023, when it slumped 97.17%.
- Macrogenics' Cost of Revenue stood at $947000.0 in 2021, then tumbled by 87.75% to $116000.0 in 2022, then soared by 40.52% to $163000.0 in 2023, then surged by 42.94% to $233000.0 in 2024.
- Business Quant data shows MGNX's Cost of Revenue at $233000.0 in Q4 2024, $168000.0 in Q3 2024, and $176000.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Macrogenics | 281.09 Mn | 167.18 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 9.53 Mn |
| Dec 31, 2025 | 10.12 Mn |
| Sep 30, 2025 | 11.59 Mn |
| Jun 30, 2025 | 8.91 Mn |
| Mar 31, 2025 | 5.40 Mn |
| Dec 31, 2024 | 5.26 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 2.65 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Sep 30, 2023 | 3.27 Mn |
| Jun 30, 2023 | 919,000.00 |
| Mar 31, 2023 | 3.41 Mn |
| Dec 31, 2022 | 798,000.00 |
| Sep 30, 2022 | 3.01 Mn |
| Jun 30, 2022 | 2.22 Mn |
| Mar 31, 2022 | 48,000.00 |
| Dec 31, 2021 | 947,000.00 |
| Sep 30, 2021 | 1.67 Mn |
| Jun 30, 2021 | 22,000.00 |
| Mar 31, 2021 | 17,000.00 |